Strategic moves from Sanofi, Inkemia and Mind the Byte

BACKGROUND

The week kicked off with Expansion’s article about the top pharma groups in the sales rankings in 2017 with GSK, Novartis and MSD at the top 3.

El Economista complemented the previous article with a review about last year’s stats on self-care industry, arising several interesting details about this area, showing the huge bet some big pharmas have made for this type of products in the last period.

At its turn, Cinco Días reviewed last year from Almirall, putting its focus on its performance in the USA. As the article announces, Almirall seems to recover after its terrible 2017 analyzing some data about company’s healthy.

SIDEGROUND

But turning our attention to what has really happened this week in the big companies, Financial Times have filtered the intention from Sanofi to sell its European generics business this year. Together with last week’s announcement of the acquisition of Ablynx, and the previous purchase of Bioverativ, also this January, these events seem to define Sanofi’s focus for the upcoming years.


Quiet week in the MidBusiness world. Inkemia published last Friday it had bought up to 238.500 shares of its own group. This represents 1,24% of its capital, executed thinking in future corporative operations.

On Tuesday, Expansion enumerated a list of the last companies who has changed its social headquarters from Barcelona to a different city in Spain. Bad news for Barcelona, which its politics to attract innovative projects to become a tech-hub are being jeopardized by the uncertainty that surrounds the Catalan region.


Week without any blockbuster sell, like the previous one was, on the little biotechs. On Tuesday, Mind the byte, announced the sign up of Oriol Segarra (previous CEO of Uriach) as new member of its Board. If you join this last recruitment to the absorption of Intelligent Pharma last month, we can forecast new big movements of the company to the international scenery in next months.

FOREGROUND

What’s next on the agenda? RTVE and several newspapers published on Tuesday that Spanish government has announced that over 3500 food products will reduce its content in salt, fats and sugars in the next three years. The project was detailed by the ministry of health on Monday.

In the field of medicine, Spain is going to be one of the first European countries to finance a 400K euros treatment, as the Ministry of Healthy announced this Wednesday (El Economista).

We ended the week with a recommendation of El Economista to invest in Shire.

 

Advertisements

One thought on “Strategic moves from Sanofi, Inkemia and Mind the Byte

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s